



6AV 1632

#20/F
CJFm
8/4/98

EXPRESS MAIL NO. EM 490 492 032 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wang et al.

Serial No.: 08/333,680 Group Art Unit: 1632

Filed: November 3, 1994 Examiner: S. Priebe

For: NOVEL ADENOVIRAL VECTORS, Attorney Docket No.: 7639-061
PACKAGING CELL LINES, (Cell 16.0)
RECOMBINANT ADENOVIRUSES,
AND METHODS

AMENDMENT UNDER 37 C.F.R. §1.111

Received

Assistant Commissioner for Patents
Washington, D.C. 20231

JUL 24 1998

GROUP 1800

Sir:

In response to the outstanding Office Action dated June 22, 1998, and pursuant to Rule 111 of the Rules of Practice please consider the following amendments and remarks.

Applicants submit herewith an appendix of the claims pending as of entry of this Amendment, attached hereto as Exhibit A.

IN THE CLAIMS:

Please amend Claims 37-39 and 46-50 as follows.

Subj
37. (amended) A replication-defective recombinant adenovirus, wherein the [adenovirus] genome of said adenovirus contains at least two lethal deletions, two lethal mutations, or one lethal deletion and one lethal mutation in the E1 and E4 early gene regions, so that the recombinant adenovirus requires for replication complementation of genes of both the E1 and E4 adenoviral early regions, wherein said recombinant adenovirus genome additionally contains a transgene [that replaces any one of said deletions].

F